TrialAdvances in therapy2025

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

Xinghua Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.